2
|
Boro S, Bannoth S, Rahman T, Das AK, Das A, Das K, Das G, Mathew A, Khandelwal K. Patient Reported Outcomes of Scalp and Forehead Reconstruction for Defects Following Oncological Resections (North-East Indian Tertiary Cancer Centre Study). Indian J Otolaryngol Head Neck Surg 2022; 74:449-455. [PMID: 36514421 PMCID: PMC9741686 DOI: 10.1007/s12070-021-02606-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 05/03/2021] [Indexed: 12/15/2022] Open
Abstract
Background Approximately 1-2% of all scalp tumours are malignant, but they comprise up to 13% of all malignant cutaneous neoplasms. The current study presents our experience of reconstruction of scalp and forehead for malignant tumours treated at our centre. Methods This is a single institutional observational study conducted at a tertiary cancer centre in North East India. Post-operative outcomes related to quality of life of patients were measured with help of FACE-Q scales. Face-Q -Satisfaction with outcome and FACE-Q- appearance related psychosocial distress scores were analysed. Histograms were used for descriptive statistics. Data were checked for normality using Kolmogorov-Smirnova and Shapiro-Wilk test. For non-normal data Wilcoxon test was used. A p value less than 0.05 was considered as statistically significant at 5% level of significance. Results Mean age of patients was 57.6 ± 14.2 years. The mean defect size was 89.036 ± 81.77 cm2. The mean satisfaction with outcome scores and distress scores at 3-months was 54.9 ± 8.6 and 34.8 ± 8.5 respectively with a statistically significant p value of 0.001.Mean satisfaction scores and psychological distress scores were better at the end of three months when compared to at the time of discharge with a statistical significant p value of < 0.0001. Conclusion Scalp and forehead reconstructions for defects following oncological resections are technically challenging and if chosen carefully with meticulous planning, both local and free tissue transfers give satisfactory outcome in long term follow up. There are lots of reconstruction options for scalp and forehead defects and knowledge of the basic bio-geometry of the each flap is must.
Collapse
Affiliation(s)
- Sumanjit Boro
- Department of Plastic Surgery, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Srinivas Bannoth
- M.ch surgical oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Tashnin Rahman
- Head and Neck Oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Ashok Kumar Das
- Head and Neck Oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Anupam Das
- Head and Neck Oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Kishore Das
- Head and Neck Oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Gaurav Das
- Surgical Oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Anil Mathew
- Department of Plastic Surgery, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| | - Kirti Khandelwal
- Mch Trainee Head and Neck Oncology, Dr. B. Borooah cancer institute, A.K.AZAD road, Gopinath nagar, Guwahati, Assam 781016 India
| |
Collapse
|
7
|
Chabaane M, Ayadi K, Rkhami M, Drissi C, Houimli S, Bahri K, Zammel I, Badri M. Management of a recurrence of a squamous cell carcinoma of the scalp with extension to the brain: A case report and literature review. Surg Neurol Int 2020; 11:347. [PMID: 33194281 PMCID: PMC7656049 DOI: 10.25259/sni_356_2020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Accepted: 09/24/2020] [Indexed: 11/28/2022] Open
Abstract
Background: Squamous cell carcinoma (SCC) is the most common form of nonmelanoma skin cancer after basal cell carcinoma. Simple excision can be the treatment at early stages of diagnosis. However, at late stages, treatment is more complex due to extension to the skull and the dura. In extremely rare cases, it can invade the brain making it a challenging situation for treatment. Case Description: We present the case of a 54-year-old man with a history of cutaneous SCC who presented an invasive left frontal recurrence with brain invasion 19 years after initial surgery. The patient underwent surgery which consisted in tumor removal and bone and skin reconstruction. Immediate and late outcomes were favorable. Conclusion: Multidisciplinary treatment for SCC diagnosed in advanced stages is the best way to obtain encouraging results. Although significant advancements have been made, further study is needed for cases with advanced disease.
Collapse
Affiliation(s)
- Mohamed Chabaane
- Department of Neurosurgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| | - Khalil Ayadi
- Department of Neurosurgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| | - Mouna Rkhami
- Department of Neurosurgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| | - Cyrine Drissi
- Department of Neuroradiology, National Institute of Neurology, Tunis, Tunisia
| | - Sarra Houimli
- Department of Plastic Surgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| | - Kamel Bahri
- Department of Neurosurgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| | - Ihsen Zammel
- Department of Neurosurgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| | - Mohamed Badri
- Department of Neurosurgery, Trauma and Burns Center Ben Arous, Ben Arous, Tunisia
| |
Collapse
|
10
|
McCabe MJ, Gauthier MEA, Chan CL, Thompson TJ, De Sousa SMC, Puttick C, Grady JP, Gayevskiy V, Tao J, Ying K, Cipponi A, Deng N, Swarbrick A, Thomas ML, Lord RV, Johns AL, Kohonen-Corish M, O'Toole SA, Clark J, Mueller SA, Gupta R, McCormack AI, Dinger ME, Cowley MJ. Development and validation of a targeted gene sequencing panel for application to disparate cancers. Sci Rep 2019; 9:17052. [PMID: 31745186 PMCID: PMC6864073 DOI: 10.1038/s41598-019-52000-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Accepted: 10/09/2019] [Indexed: 02/08/2023] Open
Abstract
Next generation sequencing has revolutionised genomic studies of cancer, having facilitated the development of precision oncology treatments based on a tumour's molecular profile. We aimed to develop a targeted gene sequencing panel for application to disparate cancer types with particular focus on tumours of the head and neck, plus test for utility in liquid biopsy. The final panel designed through Roche/Nimblegen combined 451 cancer-associated genes (2.01 Mb target region). 136 patient DNA samples were collected for performance and application testing. Panel sensitivity and precision were measured using well-characterised DNA controls (n = 47), and specificity by Sanger sequencing of the Aryl Hydrocarbon Receptor Interacting Protein (AIP) gene in 89 patients. Assessment of liquid biopsy application employed a pool of synthetic circulating tumour DNA (ctDNA). Library preparation and sequencing were conducted on Illumina-based platforms prior to analysis with our accredited (ISO15189) bioinformatics pipeline. We achieved a mean coverage of 395x, with sensitivity and specificity of >99% and precision of >97%. Liquid biopsy revealed detection to 1.25% variant allele frequency. Application to head and neck tumours/cancers resulted in detection of mutations aligned to published databases. In conclusion, we have developed an analytically-validated panel for application to cancers of disparate types with utility in liquid biopsy.
Collapse
Affiliation(s)
- Mark J McCabe
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- Hormones and Cancer Group, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- St Vincent's Clinical School, UNSW Australia, Sydney, NSW, Australia
| | - Marie-Emilie A Gauthier
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- The Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia
- Children's Cancer Institute, Randwick, NSW, Australia
| | - Chia-Ling Chan
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Tanya J Thompson
- Hormones and Cancer Group, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Sunita M C De Sousa
- Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, Australia
- Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA, Australia
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia alliance, Adelaide, SA, Australia
- School of Medicine, University of Adelaide, Adelaide, SA, Australia
| | - Clare Puttick
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - John P Grady
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Velimir Gayevskiy
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Jiang Tao
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Kevin Ying
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Arcadi Cipponi
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Niantao Deng
- St Vincent's Clinical School, UNSW Australia, Sydney, NSW, Australia
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Alex Swarbrick
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Melissa L Thomas
- St Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia
| | - Reginald V Lord
- St Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia
- Notre Dame University School of Medicine, Sydney, NSW, Australia
| | - Amber L Johns
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Maija Kohonen-Corish
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- St George and Sutherland Clinical School, UNSW Australia, Sydney, NSW, Australia
- Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia
| | - Sandra A O'Toole
- Northern Clinical School, The University of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia
- Sydney Medical School, The University of Sydney, Camperdown,, NSW, Australia
- Western Sydney University Medical School, Campbelltown, NSW, Australia
- Australian Clinical Labs, Bella Vista, NSW, Australia
| | - Jonathan Clark
- The Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia
- Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
- Central Clinical School, The University of Sydney, Sydney, NSW, Australia
| | - Simon A Mueller
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- The Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia
- Department for Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Ruta Gupta
- The Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia
- Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
- Central Clinical School, The University of Sydney, Sydney, NSW, Australia
| | - Ann I McCormack
- Hormones and Cancer Group, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- St Vincent's Clinical School, UNSW Australia, Sydney, NSW, Australia
- Department of Endocrinology, St Vincent's Hospital, Darlinghurst, NSW, Australia
| | - Marcel E Dinger
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- St Vincent's Clinical School, UNSW Australia, Sydney, NSW, Australia
| | - Mark J Cowley
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
- St Vincent's Clinical School, UNSW Australia, Sydney, NSW, Australia.
- Children's Cancer Institute, Randwick, NSW, Australia.
| |
Collapse
|